- call +1-201-465-4211
- email sales@mrinsights.biz
Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections.
Scope of the Report:
This report studies the Hospital Infection Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hospital Infection Therapeutics market by product type and applications/end industries.
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.
North America led the demand for hospital infection therapeutics market in 2017. The high prevalence of nosocomial infections has been identified as the key factor that has been driving the demand for infection therapeutics in North America and is projected to continue to do so throughout the forecast period. Although North America will remain the leading regional market for hospital infection therapeutics, it is Asia Pacific, which will present the most promising growth opportunities to this market in the near future.
The global Hospital Infection Therapeutics market is valued at 2700 million USD in 2017 and is expected to reach 3490 million USD by the end of 2023, growing at a CAGR of 4.4% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hospital Infection Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bayer
Johnson & Johnson Services
Actavis
Sanofi
Bristol Myers Squibb Company
AstraZeneca
Pfizer
Merck
GlaxoSmithkline
Cubist Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Market Segment by Applications, can be divided into
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infection
Gastrointestinal Disorders
Bloodstream Infections
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Hospital Infection Therapeutics Market Overview
1.1 Product Overview and Scope of Hospital Infection Therapeutics
1.2 Classification of Hospital Infection Therapeutics by Types
1.2.1 Global Hospital Infection Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Hospital Infection Therapeutics Revenue Market Share by Types in 2017
1.2.3 Antibacterial Drugs
1.2.4 Antiviral Drugs
1.2.5 Antifungal Drugs
1.3 Global Hospital Infection Therapeutics Market by Application
1.3.1 Global Hospital Infection Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Acquired Pneumonia
1.3.3 Surgical Site Infections
1.3.4 Urinary Tract Infection
1.3.5 Gastrointestinal Disorders
1.3.6 Bloodstream Infections
1.3.7 Others
1.4 Global Hospital Infection Therapeutics Market by Regions
1.4.1 Global Hospital Infection Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Hospital Infection Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Hospital Infection Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Hospital Infection Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Hospital Infection Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Hospital Infection Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Hospital Infection Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Hospital Infection Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bayer Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Johnson & Johnson Services
2.2.1 Business Overview
2.2.2 Hospital Infection Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Johnson & Johnson Services Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Actavis
2.3.1 Business Overview
2.3.2 Hospital Infection Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Actavis Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Hospital Infection Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol Myers Squibb Company
2.5.1 Business Overview
2.5.2 Hospital Infection Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol Myers Squibb Company Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 AstraZeneca
2.6.1 Business Overview
2.6.2 Hospital Infection Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 AstraZeneca Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Pfizer
2.7.1 Business Overview
2.7.2 Hospital Infection Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Pfizer Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Merck
2.8.1 Business Overview
2.8.2 Hospital Infection Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Merck Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 GlaxoSmithkline
2.9.1 Business Overview
2.9.2 Hospital Infection Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 GlaxoSmithkline Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Cubist Pharmaceuticals
2.10.1 Business Overview
2.10.2 Hospital Infection Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Cubist Pharmaceuticals Hospital Infection Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hospital Infection Therapeutics Market Competition, by Players
3.1 Global Hospital Infection Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Hospital Infection Therapeutics Players Market Share
3.2.2 Top 10 Hospital Infection Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Hospital Infection Therapeutics Market Size by Regions
4.1 Global Hospital Infection Therapeutics Revenue and Market Share by Regions
4.2 North America Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Hospital Infection Therapeutics Revenue by Countries
5.1 North America Hospital Infection Therapeutics Revenue by Countries (2013-2018)
5.2 USA Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Hospital Infection Therapeutics Revenue by Countries
6.1 Europe Hospital Infection Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Hospital Infection Therapeutics Revenue by Countries
7.1 Asia-Pacific Hospital Infection Therapeutics Revenue by Countries (2013-2018)
7.2 China Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Hospital Infection Therapeutics Revenue by Countries
8.1 South America Hospital Infection Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Hospital Infection Therapeutics by Countries
9.1 Middle East and Africa Hospital Infection Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Hospital Infection Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Hospital Infection Therapeutics Market Segment by Type
10.1 Global Hospital Infection Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Hospital Infection Therapeutics Market Forecast by Type (2018-2023)
10.3 Antibacterial Drugs Revenue Growth Rate (2013-2023)
10.4 Antiviral Drugs Revenue Growth Rate (2013-2023)
10.5 Antifungal Drugs Revenue Growth Rate (2013-2023)
11 Global Hospital Infection Therapeutics Market Segment by Application
11.1 Global Hospital Infection Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Hospital Infection Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospital Acquired Pneumonia Revenue Growth (2013-2018)
11.4 Surgical Site Infections Revenue Growth (2013-2018)
11.5 Urinary Tract Infection Revenue Growth (2013-2018)
11.6 Gastrointestinal Disorders Revenue Growth (2013-2018)
11.7 Bloodstream Infections Revenue Growth (2013-2018)
11.8 Others Revenue Growth (2013-2018)
12 Global Hospital Infection Therapeutics Market Size Forecast (2018-2023)
12.1 Global Hospital Infection Therapeutics Market Size Forecast (2018-2023)
12.2 Global Hospital Infection Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Hospital Infection Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Hospital Infection Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Hospital Infection Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Hospital Infection Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Hospital Infection Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Hospital Infection Therapeutics Picture
Table Product Specifications of Hospital Infection Therapeutics
Table Global Hospital Infection Therapeutics and Revenue (Mil
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
